[Effects of gamma-oryzanol and atropine on gastric secretion stimulated by insulin or 2-deoxy-D-glucose (author's transl)].
The inhibitory effects of gamma-oryzanol and atropine on the gastric secretion were studied using insulin and 2-deoxy-D-glucose as vagal stimulants. Pretreatment with gamma-oryzanol (100 mg/kg, s.c., once daily x 5) depressed the gastric secretion stimulated by insulin or 2-deoxy-D-glucose, but the potency was less than that with atropine (10 mg/kg, s.c.). gamma-Oryzanol had no effect on decrease in the serum glucose level or on increase in the gastrin level induced by insulin injection, while atropine enhanced these responses. From these results, it is considered that the inhibitory action of gamma-oryzanol on gastric secretion may be due to depression of the vagus system but the mode of action is different from that of atropine.
D000818:Animals; D001285:Atropine / Q000494:pharmacology*; D001786:Blood Glucose / Q000378:metabolism; D003837:Deoxy Sugars / Q000037:antagonists & inhibitors*; D003847:Deoxyglucose / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D005750:Gastric Juice / Q000378:metabolism*; D005755:Gastrins / Q000097:blood; D007328:Insulin / Q000494:pharmacology; D007329:Insulin Antagonists; D008297:Male; D010666:Phenylpropionates / Q000494:pharmacology*; D051381:Rats; D013268:Stimulation, Chemical; D014630:Vagus Nerve / Q000187:drug effects
D001786:Blood Glucose; D003837:Deoxy Sugars; D005755:Gastrins; D007328:Insulin; D007329:Insulin Antagonists; D010666:Phenylpropionates; D001285:Atropine; D003847:Deoxyglucose; C013172:gamma-oryzanol